Better Antigens. Better Antibodies. Better Assays.
SDIX, LLC is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical and biotechnology markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease.
In July 2013, SDIX joined OriGene, the global leader in gene-centric research tools. SDIX now has access to all the genomic, protein, and antibody reagents that OriGene has amassed over the past 17 years. Tapping into the extensive molecular biology resources of OriGene, SDIX projects will accelerate while retaining the same high standards guaranteed by the established ISO9001/GMP accreditations.
Strategic Diagnostics Inc. d/b/a SDIX. Listed on the NASDAQ: SDIX
SDIX is proud to have earned a number of certificates which shows our dedication to having a quality and respected operations.
SDIX's News & Media will help you answer your questions about our latest Press Releases, Product News, Upcoming Events and Publications.
Publications from SDIX authors and about our products and services.
Find out if SDIX will be exhibiting at the shows you'll be attending.
A brief history of SDIX -- from Strategic Diagnostics (SDI) to SDIX.